Additional file 1 of LIFU/MMP-2 dual-responsive release of repurposed drug disulfiram from nanodroplets for inhibiting vasculogenic mimicry and lung metastasis in triple-negative breast cancer

Abstract

Additional file 1: Fig. S1. Drug Loading Efficacy of Nanodroplets with Varying Feeding Ratios of DSF and PLGA-MMP-2-PEG. Fig. S2. Detection of conjugation efficiency of the FITC-labelled MMP-2-PEG and PLGA-COOH. Fig. S3. HPLC chromatograms of DSF. Table S1. Average particle size, zeta potential, drug loading and encapsulation efficiency of PFP@PD and PFP@PDM-PEG. (n=3, mean ± SD). Fig. S4. In vitro drug release profiles of PFP@PD and PFP@PDM-PEG. (n=3, mean ± SD). Fig. S5. Antitumor efficacy of PFP@PDM-PEG in vitro. Fig. S6. Representative images of the 4T1 tumors after different treatment at day 14. Fig. S7. Representative H&E staining of the liver in each group. The scale bar: 10 μm. Fig. S8. Calculation of the mean density of endothelium-dependent microvessels in each group. Fig. S9. Calculation of the fluorescence intensity of COL1 in each group. (n=3, t-test, *p < 0.05, **p < 0.01, ***p < 0.001). Fig. S10. Calculation of the fluorescence intensity of activated MMP-2 in each group. (n=3, t-test, **p < 0.01, ***p < 0.001, ****p < 0.0001). Fig. S11. All mouse hematologic and serum biomedical indices. Fig. S12. H&E staining of the vital organs (heart, liver, spleen, lungs, and kidneys). Fig. S13. Variations in body weight of 4T1 tumor-bearing mice in various groups